购物车
- 全部删除
- 您的购物车当前为空
Rilapladib (SB 659032) 是 Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) 的选择性抑制剂 (IC50 = 230 pM) 和血小板活化因子受体的拮抗剂。
为众多的药物研发团队赋能,
让新药发现更简单!
Rilapladib (SB 659032) 是 Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) 的选择性抑制剂 (IC50 = 230 pM) 和血小板活化因子受体的拮抗剂。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 946 | 现货 | |
5 mg | ¥ 2,390 | 现货 | |
10 mg | ¥ 3,890 | 现货 | |
25 mg | ¥ 6,230 | 现货 | |
50 mg | ¥ 8,570 | 现货 | |
100 mg | ¥ 11,500 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 3,880 | 现货 |
产品描述 | Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating factor receptor. |
靶点活性 | Lp-PLA2:230 pM |
体外活性 | Rilapladib reduces the PAF biological activity and levels, thereby reducing Lp-PLA2 biosynthesis and preventing the possible adverse effects of Lp-PLA2 [2]. |
别名 | 瑞拉帕地, SB 659032 |
分子量 | 735.8 |
分子式 | C40H38F5N3O3S |
CAS No. | 412950-08-4 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 78 mg/mL (106 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.